ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / XNCR
AUPH (74) VERA (31) PRGO (49) HRMY (86) ⌘ Pro Terminal →

Xencor Inc. (XNCR) — RQD Stock Rating Cockpit

$29.66 -0.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.57

Xencor Inc. (XNCR) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.22B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XNCR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XNCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Xencor Inc. (NASDAQ: XNCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $29.66 (-0.54% 1D, market cap $2.22B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XNCR ranks #302 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XNCR compare to AUPH and VERA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XNCR carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.3%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and VERA (Vera Therapeutics Inc. (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XNCR?
▼

Per XNCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326732), Xencor Inc. generated $125.6M in revenue (+13.7% YoY), -$91.9M in net income, and -$138.3M in free cash flow against $875.5M in total assets and $76.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $29.57 (-0.29%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (6)Whales (17)SEC (12)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$35 Bull$28 Base$22 Bear
📬 FREE XNCR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XNCR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY XNCR SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (36% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (26% of score)

Altman Z-Score 4.32 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$23.52+6% Next Q
Q2 (-2Q)
42
Grade D$24.94+20.2% Next Q
Q3 (-1Q)
44
Grade D$29.99-1.1% Next Q
Current
47
Grade D$29.66-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XNCR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XNCR currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.78) and Max Pain ($31.14) forces dealer call-delta covering toward $35.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XNCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XNCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
66.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
4.32>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE83% OF RANGE
L: $10$29.66H: $34
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on XNCR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-21.3% ROIC with 42.0% gross margin and -6.37% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 4.32 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (48)

20/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like XNCR
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XNCR)

  • ✓Walkthrough of XNCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XNCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +122.01%▲ ASCENDING CHANNEL
2026-11-03O $29.21H $29.82L $29.21C $29.66VOL 1.29M
RES: $34.02SUP: $23.24SMA50: $25.78SMA200: $17.12
$35.23$28.49$21.76$15.02$8.29RES $34.02SUP $23.24$29.662026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XNCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XNCR Butterfly Map → + Track XNCR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +13.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XNCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XNCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XNCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XNCR)

Health Care Rank #302 of 1015 ⚔️ AUPH vs XNCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XNCR vs. AUPH, VERA, PRGO, HRMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Xencor Inc. (XNCR) ranks #302 by composite RQD confidence (47/100, grade D) and #238 by equity capitalization ($2.22B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with XNCR at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XNCR ACTIVE
Xencor Inc.
D 47/100 — — -21.3% -0.54% $2.22B Benchmark Subject
AUPH
Aurinia Pharmaceuticals Inc
B 74/100 8.0x 88.5% 16.5% -3.06% $2.22B /auph-vs-xncr →
VERA
Vera Therapeutics Inc. (Class A)
E 31/100 — — -35.0% -2.36% $2.23B /vera-vs-xncr →
PRGO
Perrigo Company plc
D 49/100 — 35.1% -13.6% -0.19% $2.19B /prgo-vs-xncr →
HRMY
Harmony Biosciences Holdings Inc.
A 86/100 14.2x 77.2% 63.0% -2.19% $2.26B /hrmy-vs-xncr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001326732 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xencor Inc. (XNCR) reported GAAP revenue of $125.6M (+13.7% vs. FY2024 revenue of $110.5M , and -28.1% cumulative change since FY2023) , GAAP net income of -$91.9M, operating cash flow of -$135.1M, and free cash flow of -$138.3M (+33.6% YoY). On the balance sheet, XNCR closed FY2025 with $875.5M in total assets against $76.5M in total debt (Altman Z-Score: 4.32, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $125.6M -$91.9M -$135.1M -$138.3M $875.5M $76.5M
FY2024 (FY) 2024-12-31 $110.5M -$232.6M -$202.2M -$208.3M $951.9M $115.2M
FY2023 (FY) 2023-12-31 $174.6M -$133.1M -$77.9M -$77.9M — —

3. XNCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XNCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Xencor Inc. (NASDAQ: XNCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $29.66 (-0.54% 1D, market cap $2.22B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XNCR ranks #302 in composite RQD confidence.

How does XNCR compare to AUPH and VERA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XNCR carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.3%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and VERA (Vera Therapeutics Inc. (Class A)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XNCR?

Per XNCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326732), Xencor Inc. generated $125.6M in revenue (+13.7% YoY), -$91.9M in net income, and -$138.3M in free cash flow against $875.5M in total assets and $76.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XNCR trading relative to its 50-day, 200-day, and 52-week technical levels?

XNCR last traded at $29.66 (-0.54% on volume of 2,107,056 shares), positioning the stock +15.05% above its 50-day simple moving average ($25.78) and +73.25% above its 200-day simple moving average ($17.12). Across its 52-week range of $10.38 to $33.60, XNCR sits at the 83.0% percentile with a 14-day RSI of 66.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($25.95 to $33.37).

Direct Sub-Reports: XNCR RQD Cockpit XNCR 12M Forecast XNCR Earnings & Move XNCR Dividends & DRIP XNCR Insiders & 13F XNCR Whale Options XNCR Profit Sankey XNCR News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

XNCR — Xencor Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Xencor Inc. (XNCR) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $29.66 (-0.54% 1D, market capitalization $2.22B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -21.3%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -6.37%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.32, Piotroski F-Score of 4/9, and Debt/Equity of 0.12x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Xencor Inc. (XNCR) is listed on NASDAQ and classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $125.6M for FY 2025 .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Xencor Inc. (XNCR) reported $125.6M in annual revenue (up from $110.5M in FY2024, +13.7% YoY) and -$91.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($174.6M revenue, -$133.1M net income) through FY2025, XNCR scaled operating cash flow to -$135.1M and free cash flow to -$138.3M, backed by $875.5M in total assets against $76.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -6.37% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $10.38 – $33.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links are mapped, no sector correlations are provided beyond the Health Care classification, and no bottlenecks are identified.

  • Key Question #1: Can XNCR sustain or expand its -60.0% operating margin and -21.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $125.6M and free cash flow of -$138.3M, how will capital allocation balance growth reinvestment against $76.5M in total debt?
  • Key Question #3: How sensitive is XNCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XNCR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Xencor Inc. (XNCR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XNCR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XNCR Bull vs. Bear Conversation Board — What's Your Call at $29.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XNCR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XNCR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $35.49 (+19.0%)
📌 Pinned Debate

Institutional whale 13F flow scores 16 of 20 and the balance sheet shows an Altman Z of 4.32 with debt falling from $115.2M to $76.5M.

Don't sleep on XNCR's setup in Health Care. Institutional whale 13F flow scores 16 of 20 and the balance sheet shows an Altman Z of 4.32 with debt falling from $115.2M to $76.5M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (47/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

@MeanReversion_88 Shorting a 17/20 institutional whale-flow stock at $29.82 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $25.05 (-16.0%)
Spot @ $29.82

ROIC of -21.3%, FCF yield of -6.37%, and FY 2025 free cash flow of -$138.3M against $54.1M of cash point to sustained cash burn.

Here is the bear case nobody on the bull side wants to address on XNCR: ROIC of -21.3%, FCF yield of -6.37%, and FY 2025 free cash flow of -$138.3M against $54.1M of cash point to sustained cash burn.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%